← Metformin × cardiovascular events

SynthesisThe Cochrane database of systematic reviews2019

Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.

Kasper S Madsen et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 28,746 people · 2019

Range includes no effect

No clear effect on cardiovascular events

1.3×0.7× to 2.5×

Bigger than 5 in 10 for cardiovascular events

As reported

RR 1.29, 95% CI 0.67–2.47

Range includes no effect

No clear effect on cardiovascular events

1.2×0.7× to 2.1×

Bigger than 4 in 10 for cardiovascular events

As reported

RR 1.21, 95% CI 0.68–2.14

Range includes no effect

No clear effect on cardiovascular events

1.7×0.5× to 5.2×

Bigger than 8 in 10 for cardiovascular events

As reported

RR 1.68, 95% CI 0.54–5.21

Range includes no effect

No clear effect on cardiovascular events

1×0.4× to 2.1×

Smaller than almost all for cardiovascular events

As reported

RR 0.96, 95% CI 0.44–2.09

+6 more in the walkthrough ↓

Ten numbers in the abstract

the abstract, start to end

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
RR 1.290.67–2.47
Cardiovascular events
RR 1.210.68–2.14
Cardiovascular events
RR 1.680.54–5.21
Cardiovascular events
RR 0.960.44–2.09
Cardiovascular events
RR 1.220.33–4.41
Cardiovascular events
RR 1.430.49–4.18
Cardiovascular events
RR 1.020.76–1.37
Cardiovascular events
RR 1.010.93–1.11
Cardiovascular events
RR 0.780.36–1.67
Cardiovascular events
RR 2.210.74–6.58
MetforminOther glucose-loweringCardiovascular eventsAll-cause mortality
1 / 3

17 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 30998259